Trial Profile

Low-dose Interleukin-2 and Pembrolizumab Among Patients With Metastatic Melanoma and Renal Cell Carcinoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interleukin-2 (Primary) ; Pembrolizumab (Primary)
Indications Malignant melanoma; Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms UVA-AM-002

Most Recent Events

09 Jul 2019 Planned initiation date changed from 16 Oct 2017 to 29 Oct 2018.
09 Jul 2019 Status changed from recruiting to withdrawn prior to enrolment.
30 Oct 2018 Planned End Date changed from 1 May 2022 to 1 Oct 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com